Tilray Brands (NASDAQ:TLRY – Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, April 1st. Analysts expect Tilray Brands to post earnings of ($0.14) per share and revenue of $201.35 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Tuesday, April 7, 2026 at 8:30 AM ET.
Tilray Brands (NASDAQ:TLRY – Get Free Report) last issued its earnings results on Thursday, January 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.12. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.The business had revenue of $217.51 million for the quarter, compared to analysts’ expectations of $211.15 million. During the same period in the previous year, the firm posted ($0.03) EPS. On average, analysts expect Tilray Brands to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Tilray Brands Trading Down 5.8%
Shares of NASDAQ TLRY opened at $6.54 on Friday. The company has a quick ratio of 1.72, a current ratio of 2.81 and a debt-to-equity ratio of 0.19. Tilray Brands has a 12 month low of $3.51 and a 12 month high of $23.20. The company has a market cap of $761.96 million, a price-to-earnings ratio of -0.30 and a beta of 1.96. The business has a fifty day simple moving average of $7.60 and a 200-day simple moving average of $10.39.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of analysts have commented on the stock. Roth Mkm reduced their price objective on shares of Tilray Brands from $20.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Zacks Research upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tilray Brands in a research note on Wednesday, January 21st. Finally, Canaccord Genuity Group initiated coverage on Tilray Brands in a research report on Tuesday, January 27th. They issued a “hold” rating for the company. One research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $13.33.
Read Our Latest Stock Analysis on TLRY
Key Tilray Brands News
Here are the key news stories impacting Tilray Brands this week:
- Positive Sentiment: Tilray announced a licensing partnership with The Magnum Ice Cream Company to launch Popsicle® Hard ready-to-drink (5% ABV) beverages in the U.S., a nostalgic, CPG-focused play that can drive beverage revenue and expand mainstream distribution. Read More.
- Neutral Sentiment: Tilray set an April 1, 2026 pre-market release for Q3 fiscal results and will host an 8:30 AM ET webcast — a catalyst that could move the stock either direction depending on revenue, margins and guidance. Short-term volatility is likely around the print. Read More.
- Negative Sentiment: Market reaction has been negative today: coverage notes TLRY declined more than the market. The shares are trading below both the 50‑day ($7.60) and 200‑day ($10.39) moving averages and volume is below average, signaling technical weakness; near-term investor concern likely reflects uncertainty ahead of the earnings release. Read More.
About Tilray Brands
Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.
Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.
See Also
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
